Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), Oric Pharmaceuticals (ORIC – Research Report) and CytomX Therapeutics (CTMX – Research Report).
Insmed (INSM)
In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Insmed, with a price target of $40.00. The company’s shares closed last Monday at $27.08.
According to TipRanks.com, Zemansky is a 5-star analyst with an average return of
Insmed has an analyst consensus of Strong Buy, with a price target consensus of $45.40, a 63.1% upside from current levels. In a report issued on February 26, UBS also initiated coverage with a Buy rating on the stock with a $46.00 price target.
See today’s best-performing stocks on TipRanks >>
Oric Pharmaceuticals (ORIC)
Wedbush analyst David Nierengarten initiated coverage with a Buy rating on Oric Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Monday at $14.99, close to its 52-week high of $16.65.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
Oric Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $18.60, which is a 24.4% upside from current levels. In a report issued on February 29, Robert W. Baird also maintained a Buy rating on the stock with a $27.00 price target.
CytomX Therapeutics (CTMX)
In a report released today, Robert Driscoll from Wedbush maintained a Hold rating on CytomX Therapeutics, with a price target of $3.00. The company’s shares closed last Monday at $2.51.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
CytomX Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.94, which is a 16.7% upside from current levels. In a report released yesterday, BMO Capital also maintained a Hold rating on the stock with a $3.25 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INSM:
